RE:RE:RE:INTERESTING ARTICLE RE LIPID MANAGEMENT , DOSING START
JK,
Certainly could be, but you have to be careful when you go down the path of thinking about a combinational drug. While its a great excercise from a new IP perspective, its also a brand new drug which means starting nearly over unless there is large amounts if real world data on each. But as standlone drugs, they could work together. Im skpetical that they would as they are likley doing many similar things, but it's possible. My rule of thumb though is that combinational drugs to extend patents and platform technologies are for the big boys. The smaller companies really have to stay focused because like it or not, they will be judged by the success or failure of their lead compound.